More than one billion people around the world suffer from neurological conditions and diseases, and finding new, more effective treatments for patients is a high priority for Pfizer research and development.

I think this will be the norm. When you have something new, there is the theoretical potential for harm.

We're of a size and can do enough different things that we're not putting all our bets on one specific area,

I'm a big believer in size, ... When you're a smaller company, as we were 27 years ago when I started, you don't necessarily have the resources to invest in things outside your immediate expertise. But as we've gotten bigger and become more resource-rich we've been able to expand.

Is the public more cynical? Yes. There's a perception that we don't bring much to the party.

We will be the first out there and for a while.